33 research outputs found

    Treatment of hepatic cancer patients with a gluconeogenic diet: report of a case with hepatic metastases of malignant melanoma

    Get PDF
    A case of malignant melanoma with metastases mainly to the liver and the right ilium was treated with a gluconeogenic diet. The carbohydrate content of the diet was finally reduced to 5&#8764;10 g per day and the remaining calories were derived from protein and fat. Increased blood citrate and NEFA concentrations, increased ketone body formation and the maintenance of a reasonable level of blood sugar confirmed the attainment of a gluconeogenic metabolic state. Definite improvements in size of a hepatic tumor, serum alkaline phosphatase activity and the general condition were observed transient1y during the dietary therapy. Growth of the tumor resumed despite the continued gluconeogenic therapy, and the patient died of cardiac failure. Concentrations of gluconeogenic enzymes, fructose-1, 6-diphosphatase, glutamic oxaloacetic transaminase and glutamic pyruvic transaminase, were all found to be very low in the tumor tissue as expected.</p

    Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.

    Get PDF
    PURPOSE:To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related macular degeneration (AMD).METHODS:Adults aged at least 50 years old with exudative AMD and best-corrected visual acuity (BCVA) of 73-25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were included. Patients received three monthly doses of IVT-AFL 2 mg. At week 16, patients were randomized 1:1 to IVT-AFL T&E with either 2- or 4-week adjustments. The primary endpoint was mean change in BCVA from baseline to week 52. Outcomes were assessed at weeks 52 and 96.RESULTS:Baseline characteristics were comparable between the groups (n = 123 each). Over 52 weeks, mean number of injections was 7.2 and 6.9 and mean last injection interval was 10.7 and 11.8 weeks, for the 2- and 4-week groups, respectively. From baseline, mean change in BCVA was + 9.0 and + 8.4 letters (week 52) and + 7.6 and + 6.1 letters (week 96); mean change in central retinal thickness was - 134.4 µm and - 126.1 µm (week 52) and - 130.5 µm and - 125.3 µm (week 96). Last injection interval before week 52 was at least 12 weeks in 42.3% and 49.6% of patients and 56.9% and 60.2% before week 96. Over 96 weeks, mean number of injections was 10.4 (both groups). The safety profile of IVT-AFL was consistent with previous reports.CONCLUSIONS:IVT-AFL administered using two different T&E regimens for treatment-naïve exudative AMD improved functional and anatomic outcomes at week 52 and outcomes were maintained to week 96. Outcomes were similar between the 2- and 4-week groups.TRIAL REGISTRATION:ClinicalTrials.gov identifier, NCT02305238

    A Case of Revision THA with Huge Acetabular Bone Defect

    No full text
    corecore